What is Pattern Bioscience?
Pattern Bioscience is at the forefront of diagnostic innovation, developing technology that delivers rapid ID/AST results in mere hours. By leveraging single-cell microbiology, the company aims to curtail the widespread, unnecessary prescription of antibiotics in healthcare settings, thereby enhancing patient outcomes and addressing the critical global challenge of antimicrobial resistance. Their diagnostic solutions are designed for healthcare providers and cover all common infection sites, positioning Pattern Bioscience as a key player in the fight against antibiotic misuse.
How much funding has Pattern Bioscience raised?
Pattern Bioscience has raised a total of $137.7M across 5 funding rounds:
Series A
$6.4M
Series B
$15.4M
Series C
$28.7M
Private Equity
$44.2M
Series D
$43M
Series A (2019): $6.4M, investors not publicly disclosed
Series B (2020): $15.4M led by Omnimed Capital and Illumina Ventures
Series C (2023): $28.7M supported by Omnimed Capital, Antimicrobial Resistance Action Fund, Illumina Ventures, and Daleshaw
Private Equity (2025): $44.2M, investors not publicly disclosed
Series D (2025): $43M backed by Illumina Ventures and The AMR Action Fund
Key Investors in Pattern Bioscience
Illumina Ventures
Illumina Ventures is a leader in genomics and precision health investing, focused on building an ecosystem that translates investment into innovation to enhance human health. The company supports various portfolio companies that are advancing life science research, biopharmaceutical drug development, and gene editing technologies.
The AMR Action Fund
The AMR Action Fund is dedicated to overcoming technical and funding barriers in antibiotic development, aiming to ensure a sustainable pipeline of new antibiotics to combat superbugs. They invest in biotechnology companies that are creating treatments for patients with life-threatening antimicrobial-resistant infections.
Omnimed Capital
Omnimed Capital is an investor that has participated in multiple funding rounds for Pattern Bioscience, indicating a strategic interest in the company's diagnostic solutions.
What's next for Pattern Bioscience?
The substantial enterprise-level capital infusion, highlighted by the recent strategic investment, positions Pattern Bioscience for accelerated growth and market expansion. This backing is expected to fuel further research and development, enhance manufacturing capabilities, and broaden the company's commercial reach. The company's focus on delivering faster, smarter diagnostic solutions for infection sites is critical in the ongoing battle against superbugs, suggesting a future trajectory aimed at solidifying its market leadership and impact on global public health.
See full Pattern Bioscience company page
